Targeting BRAF-mutant glioma: reflections on the ROAR trial
- PMID: 34838157
- DOI: 10.1016/S1470-2045(21)00662-8
Targeting BRAF-mutant glioma: reflections on the ROAR trial
Conflict of interest statement
KBP reports research funding from Agios, Servier, Abbvie, BioMimetix; reports honoraria for a lecture from Eisai; was on the advisory board for Agios and Bayer; and is on the advisory board for Vivacitas Oncology and Sapience.
Comment on
-
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.Lancet Oncol. 2022 Jan;23(1):53-64. doi: 10.1016/S1470-2045(21)00578-7. Epub 2021 Nov 24. Lancet Oncol. 2022. PMID: 34838156 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials